Important mammalian veterinary viral immunodiseases and their control

Vaccine

Volumn 30, Issue 10, 2012, Pages 1767-1781

  Patel, J R ^a   Heldens, J G M ^b   Bakonyi, T ^c   Rusvai, M ^c  

^a Denny Industrial Estate   (United Kingdom)

^b Merck Sharpe and Dohme Animal Health   (Netherlands)

^c SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

Veterinary viral immunodiseses, immunopropylaxis

Indexed keywords

VIRUS ANTIBODY; VIRUS VACCINE;

AFRICAN SWINE FEVER; AFRICAN SWINE FEVER VIRUS; ALEUTIAN MINK DISEASE; BOVINE DIARRHEA VIRUS; BOVINE LEUKEMIA VIRUS; BOVINE VIRAL DIARRHEA; CANINE DISTEMPER; CAPRINE ARTHRITIS ENCEPHALITIS; CAPRINE ARTHRITIS ENCEPHALITIS VIRUS; CORONAVIRUS; EQUINE INFECTIOUS ANEMIA; EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; FELINE INFECTIOUS PERITONITIS; FELINE LEUKEMIA; HERPES VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTION CONTROL; LENTIVIRINAE; MAEDI VISNA; MALIGNANT CATARRHAL FEVER; MAMMALIAN DISEASE; NONHUMAN; PARAMYXOVIRUS; PARVOVIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; VIRAL TROPISM; VIRUS INFECTION; VIRUS REPLICATION; VISNA VIRUS;

ANIMAL DISEASES; ANIMALS; LIVESTOCK; MAMMALS; PETS; VIRAL VACCINES; VIRUS DISEASES;

EID: 84857451484     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.014     Document Type: Review

References (239)

1. Oldstone M.B.A. Viruses can cause disease in the absence of morphological evidence of cell injury: implications for uncovering new diseases in the future. J Infect Dis 1989, 159:384-389.
2. Plotkin S.A., Vaheri A. Human fibroblasts infected with rubella virus produce a growth inhibitor. Science 1967, 156:659-661.
3. Zinkernagel R.M. Virus-induced acquired immune suppression by cytotoxic T cell-mediated immunopathology. Vet Microbiol 1992, 33:13-18.
4. Narayan O., Clements J.E. Biology and pathogenesis of lentiviruses. J Gen Virol 1989, 70:1617-1639.
5. Goff SP. Retroviridae: the retroviridae and their replication. In: Knipe DM, Howley PM, editors. Fields virology, 5th edition. Philadelphia, USA: Lippincott, Williams and Wilkins; 2007.
6. Egberink H., Horzinek M.C. Animal immunodeficiency viruses. Vet Microbiol 1992, 33:311-331.
7. Trautwein G. Immune mechanisms in the pathogenesis of viral diseases: a review. Vet Microbiol 1992, 33:19-34.
8. Desport M. Lentiviruses and macrophages: molecular and cellular interactions 2010, Caister Academic Press, Norwich, UK, p. 346.
9. Akahata W., Yang Z.Y., Andersen H., Sun S., Holdaway H.A., Kong W.P., et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010, 16(3):334-338.
10. Cheevers W.P., McGuire T.C. Equine infectious anaemia virus: immunopathogenesis and persistence. Rev Infect Dis 1985, 7:83-88.
11. Issel C.J., Foil L.D. Studies on equine infectious anemia virus transmission by insects. J Am Vet Med Assoc 1984, 184:293-297.
12. Issel C.J., Rushlow K., Foil L.D., Montelaro R.C. A perspective on equine infectious anemia with an emphasis on vector transmission and genetic analysis. Vet Microbiol 1988, 17(3):251-286.
13. Campbell R.S., Robinson W.F. The comparative pathology of the lentiviruses. J Compar Pathol 1998, 119(4):333-395.
14. Issel C.J., Coggins L. Equine infectious anaemia virus: current knowledge. J Am Vet Med Assoc 1979, 174:727-733.
15. McGuire T.C., Crawford T.B., Henson J.B. Immunofluorescent localization of equine infectious virus in tissue. Am J Pathol 1971, 62:283-294.
16. Montelaro RC, Ball JM, Rushlow KE. Equine retroviruses. In: Levy JA, editor. The retroviridae, volume 4. New York: Plenum Press; 1993. p. 257-360.
17. Craigo JK, Montelaro RC. Equine infectious anemia virus (retroviridae). In Mahy BWJ, Regenmortel MHV, editors. Encyclopedia of virology, third edition. Oxford: Academic Press; 2008. p. 167-174.
18. Harrold S.M., Cook S.J., Cook R.F., Rushlow K.E., Issel C.J., Montelaro R.C. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 2000, 74:312-321.
19. Cohen J. HIV/AIDS in China, vaccine development with a distinctly Chinese flavor. Science 2004, 304(5676):1437.
20. Shen RX, Wang Z. Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine. EIAV: a national review on policies, programs, and future objectives. Amarillo Texas USA: American Quarter Horse Association; 1985.
21. Shen RX, Wang ZY, Dong JP. Fetal Donkey Dermal cells adapted vaccine of equine infectious anemia virus and its culture method. Chinese patent no. 01123620; 2001.
22. Shen R.X., Xu Z.D., He X.S., Zhang S.X. Study on immunological methods of equine infectious anemia. Chin Agric Sci 1979, 4:1-15.
23. Ma J., Shi N., Jiang C.G., Lin Y.Z., Wang X.F., Wang S., et al. A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity. Virology 2011, 410(1):96-106.
24. Craigo J.K., Montelaro R.C. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr HIV Res 2010, 8(1):81-86.
25. Craigo J.K., Zhang B., Barnes S., Tagmyer T.L., Cook S.J., Issel C.J., et al. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 2007, 104(38):15105-15110.
26. Craigo J.K., Barnes S., Cook S.J., Issel C.J., Montelaro R.C. Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 2010, 28(51):8095-8104.
27. Kono Y. Recurrences of equine infectious anaemia. In: Bryans JT, Gerber H, editors. Proceedings of the 3rd international conference on equine infectious diseases. Basel: S Karger; 1972. p. 175-186.
28. Kono Y., Kobayashi K., Fukunaga Y. Serological comparison among various strains of equine infectious anaemia virus. Arch Gesamte Virusforsch 1971, 34:202-208.
29. Kono Y., Kobayashi K., Fukunaga Y. Antigenic drift of equine infectious anaemia virus in chronically infected horses. Arch Gesamte Virusforsch 1973, 41:1-10.
30. Montelaro R.C., Parekh B., Preggo A., Issel C.J. Antigenic variation during persistent infection by equine infectious anaemia virus, a retrovirus. J Biochem Chem 1984, 259:10539-10544.
31. McGuire T.C, Fraser D.G., Mealy R.H., Cytotoxic T. lymphocytes in protection against equine infectious anemia virus. Anim Health Res Rev 2004, 5(2):271-276.
32. Newman M.J., Issel C.J., Traux R.E., Powell H.D., Horohov D.W., Montelaro R.C. Transient suppression of equine immune responses by equine infectious anemia virus (EIAV). Virology 1991, 184(1):55-66.
33. Scott J.V., Stowring L., Hasse At, Narayan O., Vinge R. Antigenic variation in visna virus. Cell 1979, 18:321-327.
34. Clements J.E., Pederson S., Narayan O., Haseltine W.A. Genomic changes associated with antigenic variation of visna virus during persistent infection. Proc Natl Acad Sci U S A 1980, 77:4454-4458.
35. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., Montelaro R.C. Immunisation with recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 1998, 245:151-162.
36. Rusvai M., Bakonyi T., Hornyák A., Balka G., Hans A., Nowotny N. RT-PCR detection and phylogenetic analysis of Hungarian equine infectious anaemia virus strains. Proceedings of the 8th international congress of veterinary virology 2009.
37. Leroux C., Mornex J.F. Retroviral infections in sheep and the associated diseases. Small Rumin Res 2008, 76(1-2):68-76.
38. Peterhans E., Greenland T., Badiola J., Harkiss G., Bertoni G., Amorena B., et al. Routes of transmission and consequences of small ruminant lentiviruses (SRLVs) infection and eradication schemes. Vet Res 2004, 35:257-274.
39. Bertoni G, Blacklaws B. Small ruminant lentiviruses and cross-species transmission. In: Desport M, editor, Lentiviruses and macrophages: molecular and cellular interactions. Norfolk: Caister Academic Press; 2010. p. 277-306.
40. Blacklaws B.A., Berriatua E., Torsteinsdottir S., Watt N.J., De Andres D., Klein D., et al. Transmission of small ruminant lentiviruses. Vet Microbiol 2004, 101(3):199-208.
41. Reina R., Berriatua E., Luján L., Juste R., Sánchez A., de Andrés D., et al. Prevention strategies against small ruminant lentiviruses: an update. Vet J 2009, 182:31-37.
42. Berriarua E., Alvarez V., Extramania B., Gonzales L., Daltabuit M., Juste R.A. Transmission and control implications of seroconversion to Maedi-Visna virus in Basque dairy sheep flocks. Prevent Vet Med 2003, 60:265-279.
43. Houwers D.J., Visscher A.H., Dfize P.R. Importance of ewe/lamb relationship and breed in the epidemiology of maedi-visna virus infections. Res Vet Sci 1989, 46:5-8.
44. Brodie S.J., de la Concha-Bermejillo A., Koenig G., Snowder G.D., De Martini J.C. Maternal factors associated with prenatal transmission of ovine lentivirus. J Infect Dis 1994, 169:653-657.
45. Houwers D.J., Konig C.D.W., Bakker J., de Boer M.J., Pekelder J.J., Sol J., et al. Maedi-visna control in sheep III. Results and evalution of voluntary control program in the Netherlands over a period of four years. Vet Quart 1987, 9:29-36.
46. Crawford T.B., Adams D.S., Cheevers W.P., Cork L.C. Chronic arthritis in goats caused by a retrovirus. Science 1980, 207:997-999.
47. Gorrell M.D., Brandon M.R., Sheffer D., Adams R.J., Narayan O. Ovine lentivirus is macrophagetropic and does not replicate in T lymphocytes. J Virol 1992, 66:2679-2688.
48. Brodie S.J., Pearson L.D., Zink M.C., Bickle H.M., Anderson B.C., Marcom K.A., et al. Ovine lentivirus expression and disease-virus replication but not entry, is restricted to macrophages of specific tissues. Am J Pathol 1995, 146:250-263.
49. Ryan S., Tiley L., McConnell I., Blacklaws B. Infection of dendritic cells by the maedi-visna lentivirus. J Virol 2000, 74:10096-10103.
50. Narayan O., Kennedy-Stoskopf S., Sheffer D., Griffin D.E., Clements J.E. Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun 1983, 41:67-73.
51. Haase A.T Pathogenesis of lentivirus infections. Nature 1986, 322:130-136.
52. Haase A.T. Pathogenesis of slow virus infections: molecular analyses. J Infect Dis 1986, 153:441-447.
53. Narayan O., Wolinsky J.S., Clements J.E., Standberg J.D., Griffin D.E., Cork L.C. Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheepand goats. J Gen Virol 1982, 59:245-256.
54. Bird P., Blacklaws B., Reyburn H.T., Allen D., Hopkins J., Sargan D., et al. Early events in immune evasion by the lentivirus maedi-visna occurring within infected lymphoid tissue. J Virol 1993, 67(9):5187-5197.
55. + T-cells are required for the establishment of maedi-visna infection in macrophages but not dendritic cells in vivo. Virology 1999, 258:355-364.
56. Gendelman H.E., Narayan O., Kennedy-Stoskopf S., Kennedy P.G.E., Ghotbi Z., Clements J.E., et al. Tropism of of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol 1986, 58:67-74.
57. Gabuzda D.H., Hess J.L., Small J.A., Clements J.E. Regulation of the visna virus long terminal repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites. Mol Cell Biol 1989, 9(6):2728-2733.
58. Small J.A, Bieberich C., Ghotbi Z., Hess J., Scangos G.A., Clements J.E. The visna virus long terminal repeat directs expression of a receptor gene in activated macrophages, lymphocytes, and the central nervous systems of transgenic mice. J Virol 1989, 63(5):1891-1896.
59. Murphy B.G., Hötzel I., Jasmer D.P., Davis W.C., Knowles D. TNFα and GM-CSF-induced activation of the CAEV promoter is dependent of AP-1. Virology 2006, 352(1):188-199.
60. Murphy B., Jasmer D.P., White S.N., Knowles D. Localization of a TNF-activated transcription site and the interactions with the gamma activated site within the CAEV U3 70 base pair repeat. Virology 2007, 364(1):196-207.
61. Narayan O, Zink M, Crane S, Huso D, Jolly P, Saltarelli M, et al. The lentiviruses of sheep and goats. In: Levy JA, editors, The retroviridae. New York: Plenum press; 1993. p. 229-256.
62. Pepin M., Vitu C., Russo P., Mornex J.F., Peterhans E. Maedi-visna virus infection in sheep: a review. Vet Res 1998, 29:341-367.
63. Cheevers W.P., Beyer J.C., Hotzel L., Plasmid DNA encoding caprine interferon gamma inhibits antibody response to caprine arthritis-encephalitis virus (CAEV) surface protein encoded by a co-administered plasmid expressing CAEV env and tat genes. Vaccine 2001, 19:3209-3215.
64. Cheevers W.P., Snekvik K.R., Trujillo J.D., Kumpula-McWhirter N.M., Pretty On Top K.J., Knowles D.P. Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and virus SU suppresses challenge virus and development of arthritis. Virology 2003, 306:116-125.
65. Harmarche A., Vitu C., Guiguen F., Russo P., Bertoni G., Pepin M., et al. Priming with tat-deleted caprine arthritis encephalitis virus (CAEV) proviral DNA or live virus protects goats from challenge with pathogenic CAEV. J Virol 1998, 72:6796-6804.
66. McGuire T.C., Adams D.S., Johnson G.C., Klevjer-Anderson P., Barbee D.D., Gorman J.R. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. Am J Vet Res 1986, 47:537-540.
67. Nathanson N., Martin J.R. The effect of post-infection immunisation on the severity of experimental visna. J Compar Pathol 1981, 91:185-191.
68. Nenci C., Zahno M.-L., Vogt H.-R., Obexer-Ruff G., Doherr M.G., Zanoni R., et al. Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo. J Gen Virol 2007, 88:1589-1593.
69. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotopic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235:790-793.
70. Yamamoto J.K., Sparger E., Ho E.W., Andersen P.R., O'Connor T.P., Mandell C.P., et al. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 1988, 49:1246-1258.
71. Dow S.W., Poss M.L., Hoover E.A. Feline immunodeficiency virus: a neurotopic lentivirus. J Acquird Immunodef Synd 1990, 3:658-668.
72. Sparger E. Current thoughts on feline immunodeficiency virus infection. Vet Clin N Am Small Anim Pract 1993, 23:173-191.
73. Hosie M.J., Addie D., Belák S., Boucraut-Baralon C., Egberink H., Frymus T., et al. Feline immunodeficiency. ABCD guidelines on prevention and management. J Feline Med Surg 2009, 11(7):575-584.
74. O'Neill L.L., Burkhard M.J., Hoover E.A. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J Virol 1996, 70:2894-2901.
75. Burkhard M.J., Dean G.A. Transmission and immunopathogenesis of FIV in cats as model for HIV. Curr HIV Res 2003, 1:15-29.
76. English R.V., Johnson C.M., Gebhard D.H., Tompkins M.B. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993, 67:5175-5186.
77. Dean G.A., Reubel G.H., Moore P.F., Pedersen N.C. Proviral burden and infection kinetics of immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol 1996, 70:5165-5169.
78. Beebe A.M., Dua N., Faith T.G., Moore P.F., Pedersen N.C., Dandeker S. Primary stage of FIV infection: viral dissemination and cellular targets. J Virol 1994, 68:3080-3091.
79. Fevereiro M., Roneker C., Laufs A., Tavares L., deNoronha F. Characterisation of two monoclonal antibodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralising antibody activity. J Gen Virol 1991, 72:617-622.
80. Song W., Collisson E.W., Billingsley P.M., Brown W.C. Induction of feline immunodeficiency virus-specific cytotoxic T-cell responses from experimentally infected cats. J Virol 1992, 66:5409-5417.
81. Joshi A., Garg H., Tompkins M.B., Tompkins W.C. Preferential feline immunodeficiency virus (FIV) infection of CD4+CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors. J Virol 2005, 79:4965-4976.
82. Vahlenkamp T.W., Tompkins M.B., Tompkins W.A. Feline immunodeficiency virus infection phenotypically and functionally activates CD4+CD25+ T regulatory cells. J Immunol 2004, 172:4752-4761.
83. Lecollinet S., Richardson J. Vaccination against the feline immunodeficiency virus: the road not taken. Compar Immunol Microbiol Infect Dis 2008, 31(2-3):167-190.
84. Hohdatsu T., Okada S., Motokawa K., Aizawa C., Yamamoto J.K., Koyama H. Effect of dual-subtype vaccine against feline immunodeficiency virus infection. Vet Microbiol 1997, 58(2-4):155-165.
85. Pu R., Coleman J., Omori M., Arai M., Hohdatsu T., Huang C., et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 2001, 15(10):1225-1237.
86. Huang C., Conlee D., Loop J., Champ D., Gill M., Chu H.J. Efficacy and safety of a feline immunodeficiency virus vaccine. Anim Health Res Rev 2004, 5(2):295-300.
87. Kusuhara H., Hohdatsu T., Okumura M., Sato K., Suzuki Y., Motokawa K., et al. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol 2005, 108(3-4):155-165.
88. Huang C., Conlee D., Gill M., Chu H.J. Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge. J Feline Med Surg 2010, 12(6):451-457.
89. Dunham S.P., Bruce J., MacKay S., Golder M., Jarrett O., Neil J.C. Limited efficacy of an inactivated feline immunodeficiency virus vaccine. Vet Record 2006, 158(16):561-562.
90. Uhl E.W., Martin M., Coleman J.K., Yamamoto J.K. Advances in FIV vaccine technology. Vet Immunol Immunopathol 2008, 123(1-2):65-80.
91. Richardson J., Moraillon A., Baud S., Cuisiner A.H., Sonigo P., Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997, 71:9640-9649.
92. Hosie M., Osbourne R., Yamamoto J.K., Neil J.C., Jarrett O. Protection against homologus but not hetrologus challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol 1995, 69:1253-1255.
93. Hosie M.J., Flynn J.N., Rigby M.A., Cannon C., Dunsford T., Mackay N.A., et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol 1998, 72:7310-7319.
94. Flynn J.N., Cannon C.A., Neil J.C., Jarrett O. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune response in cats but not confer protection. J Virol 1997, 71:7586-7592.
95. Patel J.R., Heldens J.G.M. Review of companion animal viral diseases and immunoprophylaxis. Vaccine 2009, 27:491-504.
96. Matteucci D., Poli A., Mazzetti P., Sozzi S., Bonci F., Isola P., et al. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 2000, 74(23):10911-10919.
97. Pedersen NC. Feline leukemia virus. In: Appel MJ, editor, Virus infections of carnivores. Amsterdam: Elsevier Science; 1987. p. 299-320.
98. Hardy WD Jr. Immunopathology induced by the feline leukemia virus. In: Miescher PA, Muller-Eberhard HJ, editors, Springer Seminar in Immunopathology 1982;5:75-106.
99. Lutz H., Addie D., Belák S., Boucraut-Baralon C., Egberink H., Frymus T., et al. Feline leukaemia. ABCD guidelines on prevention and management. J Feline Med Surg 2009, 11(7):565-574.
100. Anderson M.M., Lauring A.S., Burns C.C., Overbaugh J. Identification of a cellular cofactor required for infection by feline leukemia virus. Science 2000, 287(5459):1828-1830.
101. Neil J.C., Onions D.E. Feline leukaemia viruses: molecular biology and pathogenesis. Anticancer Res 1985, 5:49-64.
102. Olsen R.G., Lewis M.G., Lafrado L.J., Mathes L.E., Haffer K., Sharpee R. Feline leukemia virus: current status of the feline induced immune depression and immunoprevention. Cancer Metast Rev 1987, 6:243-260.
103. Ogilvie G.K, Tompkins M.B., Tompkons W.A.F. Clinical and immunologic aspects of FeLV-induced immunosuppression. Vet Microbiol 1988, 17:287-296.
104. Overbaugh J., Donahue P.R., Quackenbush S.L., Hoover E.A., Mullins J.I. Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science 1988, 239:906-910.
105. Snyder H.W., Jones F.R., Day N.K., Hardy W.D. Isolation and characterisation of circulating feline leukemia virus immune complexes from plasma of persistently infected pet cats removed by ex vivo immunosorption. J Immunol 1982, 128:2726-2730.
106. Jarrett O., Ganiere J.P. Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine. Vet Record 1996, 138:7-11.
107. Legendre A.M., Hawks D.M., Sebring R., Rohrbach L., Chavez L., Chu H.J., et al. Comparision of the efficacy of the commercial feline leukemia virus vaccines in a natural exposure challenge. J Am Vet Med Assoc 1991, 199:1456-1462.
108. Pollock R.V., Scarlett J.M. Randomised blind trial of A commercial FeLV vaccine. J Am Vet Med Assoc 1990, 196:611-616.
109. Sparkes A.H. Feline leukaemia virus and vaccination. J Feline Med Surg 2003, 5(2):97-100.
110. Porter D.D., Larsen A.E. Statistical survey of Aleutian disease in ranch mink. Am J Vet Res 1964, 25:1226-1229.
111. Porter D.D., Larsen A.E., Porter H.G. Aleutian Disease of Mink. Adv Immunol 1980, 29:261-286.
112. Larsen A.E., Porter D.D. Pathogenesis of Aleutian disease of mink. Identification of nonpersistent infections. Infect Immun 1975, 11(1):92-94.
113. Bloom M.E., Kanno H., Mori S., Wolfinbarger J.L. Aleutian mink disease: puzzles and paradigms. Infect Agents Dis 1994, 3:271-301.
114. Best S.M., Bloom M.E. Pathogenesis of Aleutian mink disease parvovirus and similarities to b19 infection. J Vet Med B Infect Dis Vet Public Health 2005, 52(7-8):331-334.
115. Porter D.D., Larsen A.E., Porter H.G. The pathogenesis of Aleutian disease of mink: in vivo viral replication and the host antibody response to viral antigen. J Exp Med 1969, 130:579-589.
116. Roth S., Kaaden O.-R., Van Dawen S., Moennig V. Aleutian disease virus in B and T lymphocytes from blood and spleen and bone marrow cells from naturally infected mink. Intervirology 1984, 22:211-217.
117. Kaaden O.-R., Haas L., Lochelt M., Roth S. Replication of Aleutian disease virus in mink lymphocytes infected in vitro. Intervirology 1986, 25:201-209.
118. Kaaden O.-R., Bartel E., Haas L., Kierek-Jaczszuk D., Lochel M., Neth R., et al. Mechanisms contributing to the virus persistence in Aleutian disease. Dtsch Tierartzl Wochenschr 1990, 97:96-99.
119. Wohlsein P, Trautwein G, Stolze B, Haas L, Kaaden O-R. Antigen distribution in organs of mink with Aleutian disease parvovirus infection. J Vet Med 1990;B37:651-659.
120. Porter D.D., Porter H.G., Larsen A.E. Much of the increased IgG in Aleutian disease of mink is viral antibody. J Exp Pathol 1984, 1:79-88.
121. Kanno H., Wolfinbarger J.B., Bloom M.E. Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection. J Virol 1993, 67(12):7017-7024.
122. Porterfield J.S. Immunological enhancement and the pathogenesis of dengue haemorrhagic fever. J Hyg Camb 1982, 89:355-364.
123. Mims C.A. Immunopathology in virus disease. Philos Trans R Soc Lond 1983, B303:189-193.
124. Bloom M.E., Best S.M., Hayes S.F., Wells R.D., Wolfinbarger J.B., McKenna R., et al. Identification of aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation. J Virol 2001, 75(22):11116-11127.
125. Mahalingam S., Lidbury B.A. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc Natl Acad Sci U S A 2002, 99(21):13819-13824.
126. Suhrbier A., La Linn M. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 2003, 24(4):165-168.
127. Alexandersen S. Acute interstitial pneumonia in mink kits: experimental reproduction of the disease. Vet Pathol 1986, 23:579-588.
128. Moller M., Aasted B. DNA vaccination with the Aleutian mink disease virus NS1 gene confers partial protection against disease. Vaccine 2005, 23:1225-1231.
129. Aasted B., Alexandersen S., Christensen J. Vaccination with Aleutian mink disease parvovirus (AMDV) capsid proteins enhances disease while vaccination with the major non-structural AMDV protein causes partial protection from disease. Vaccine 1998, 16:1158-1165.
130. Sips G.J., Chesik D., Glazenburg L., Wilschut J., De Keyser J., Wilczak N. Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Rev Med Virol 2007, 17:223-2244.
131. Appel M.J., Shek W.R., Summers B.A. Lymphocyte-mediated immune cytotoxicity in dogs infected with virulent canine distemper virus. Infect Immun 1982, 37:592-600.
132. Cerruti-Sola S., Kristensen F., Vandevelde M., Bichsel P., Kihm U. Lymphocyte responsiveness to lectin and myelin antigens in canine distemper infection in relation to the development of demyelinating lesions. J Neuroimmunol 1983, 4:77-90.
133. Beineke A., Puff C., Seehusen F., Baumgartner W. Pathogenesis and immunopathology of systemic and nervous canine distemper. Vet Immunol Immunopathol 2009, 127:1-18.
134. Wenzlow N.P., Plattet P., Wittek R., Zurbriggen A., Grone A. Immunohistoochemical demonstration of the putative canine distemper virus receptor CD10 in dogs with and without distemper. Vet Pathol 2007, 44:943-948.
135. Sykes J.E. Immunodeficiencies caused by infectious diseases. Vet Clin N Am Small Anim Pract 2010, 40(3):409-423.
136. Appel M.J. Pathogenesis of canine distemper. Am J Vet Res 1969, 30:1167-1182.
137. Appel MJ. Canine distemper virus. In: Horzinek MCM, editor, Virus infections of vertebrates, volume 1. Elsevier Science Publishers B.V., Amsterdam, Oxford, New York, Tokyo; 1987. p. 133-159.
138. Rudd P.A., Cattaneo R., Von Messling V. Canine distemper virus uses both the anterograde and hematogenous pathway for neuroinvasion. J Virol 2006, 80:9361-9370.
139. Vandevelde M., Zurbriggen A. Demyelination in canine distemper virus infection: a review. Acta Neuropathol 2005, 109:56-68.
140. McCullough B., Krakowa S., Koestner A. Experimental canine distemper virus-induced demyelination. Lab Invest 1974, 31:216-222.
141. Appel M.J., Mendeelson S.G., Hall W.W. Macrophage Fc receptors control infectivity and neutralisation of canine distemper virus-antibody complexes. J Virol 1984, 51:643-649.
142. Vandevelde M., Zurbriggen A., Steck A., Bichsel P. Studies on the intrathecal humoral immune response in canine distemper encephalitis. J Neuroimmunol 1986, 11:41-51.
143. Krakowa S., McCullough B., Koester A., Olsen R. Myelin-specific autoantibodies associated with central nervous system demyelination in canine distemper virus infection. Infect Immun 1973, 8:819-827.
144. Barrett T., Morbillivirus infections with special emphasis on morbilliviruses of carnivores. Vet Microbiol 1999, 69:3-13.
145. Osterhaus A., Vedder E.J. A morbillivirus causing recent seal deaths. Nature 1988, 335:20.
146. Kock R., Chalmers W.S., Mwanzia J., Chillingworth C., Wambua J., Coleman P.G., et al. Canine distemper antibodies in lions of the Masai Mara. Vet Record 1998, 142(24):662-665.
147. Plowright W. Malignant catarrhal fever virus. In: Dinter Z, Morein BM, editors, Virus infections of ruminants. Amsterdam, Oxford, New York, Tokyo: Elsevier Science Publishers; 1990. p. 123-150.
148. Reid H.W., Buxton D. Malignant catarrhal fever of deer. Proc R Soc Edinb 1984, 82B:261-293.
149. Loken T., Aleksandersen M., Reid H., Pow I. Malignant catarrhal fever caused by ovine herpesvirus 2 in pigs in Norway. Vet Record 1998, 143:464-467.
150. Schultheiss P.C., Collins J.K., Spraker T.R., DeMartini J.C. Epizootic malignant catarrhal fever in three bison herds: differences from cattle and association with ovine herpesvirus-2. J Vet Diagn Invest 2000, 12:497-502.
151. Reid H.W., Bridgen A. Recovery of a herpesvirus from a roan antelope (Hippotragus equines). Vet Microbiol 1991, 28:269-278.
152. Li H., Dyer N., Keller J., Crawford T.B. Newly recognised herpesvirus causing malignant fever in white-tailed deer (Odocoileus virginianus). J Clin Microbiol 2000, 38:1313-1318.
153. Li H., Keller J., Knowles D.P., Crawford T.B. Recognition of another member of the malignant catarrhal fever virus group: an epidemic gamma herpesvirus in domestic goats. J Gen Virol 2001, 82:227-232.
154. Crawford T.B., Li H., Rosenburg S.R., Norhausen R.W., Garner M.M. Mural folliculitis and alopecia caused by infection with goat- associated malignant catarrhal fever virus in two sika deer. J Am Vet Med Assoc 2002, 221:843-847.
155. Vikoren T., Li H., Lillehaug A., Jonassen C.M., Brockerman I., Handeland K. Malignant catarrhal fever in frr-ranging cervids associated with OvHV-2 and CpHV-2 DNA. J Wildlife Dis 2006, 42:797-807.
156. Plowright W., Ferris R.D., Scott G.R. Blue wildebeest and the aetiological agent of bovine malignant catarrhal fever. Nature 1960, 188:1167-1169.
157. Mushi E.Z., Rurangirwa F.R., Karstad L. Shedding of malignant catarrhal fever virus by wildebeest calves. Vet Microbiol 1981, 6:281-286.
158. Baxter S.I.F., Wiyono A., Pow I., Reid H.W. Identification of ovine herpesvirus-2 infection in sheep. Arch Virol 1997, 142:823-831.
159. Li H., Snowder G., O'Toole D., Crawford T.B. Transmission of ovine herpesvirus 2 in lambs. J Clin Microbiol 1998, 36:223-226.
160. Russell G.C., Stewart J.P., Haig D.M. Malignant catarrhal fever: a review. Vet J 2009, 179:324-335.
161. Plowright W. Studies on malignant catarrhal fever of cattle. PhD Thesis, University of Pretoria, South Africa; 1964.
162. Taus N.S., Traul D.L., Oaks J.L., Crawford T.B., Lewis G.S., Li H. Experimental infection of sheep with ovine herpesvirus 2 via aerosolisation of nasal secretions. J Gen Virol 2005, 86:575-579.
163. Taus N.S., Oaks J.L., Gailbreath K., Traul D.L., O'Toole D., Li H. Experimental aerosol infection of cattle (Bos Taurus) with ovine herpesvirus 2 using nasal secretions from infected sheep. Vet Microbiol 2006, 116:29-36.
164. Reid H.W., Buxton D., Pow I., Finlayson J. Malignant catarrhal fever- experimental transmission of the sheep-associated form of the disease from cattle and deer to cattle, deer, rabbits and hamsters. Res Vet Sci 1986, 41:76-81.
165. Cleaveland S., Laurenson M.K., Taylor L.H. Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Philos Trans R Soc Lond Ser B Biol Sci 2001, 356(1411):991-999.
166. Bedelian C., Nkedianye D., Herrero M. Masai perception of the impact and incidence of malignant catarrhal fever (MCF) in southern Kenya. Prevent Vet Med 2007, 78:296-316.
167. Buxton D., Reid H.W., Finlayson J., Pow I. Pathogenesis of sheep-associated malignant catarrhal fever in rabbits. Res Vet Sci 1984, 36:205-211.
168. Schock A., Reid H.W. Characterisation of the lymhoproliferation in rabbits experimentally affected with malignant catarrhal fever. Vet Microbiol 1996, 53:111-119.
169. Simon S., Li H., O'Toole D., Crawford T.B., Oaks J.L. The vascular lesions of a cow and bison with sheep-associated malignant catarrhal fever contain ovine herpesvirus 2-infected CD8+ T lymphocytes. J Gen Virol 2003, 84:2009-2013.
170. Piercy S.E. Studies of bovine malignant catarrha. VI. Adaptation to rabbits. Br Vet J 1955, 111:484-491.
171. Bridgen A., Reid H.W. Derivation of a DNA clones corresponding to the viral agent of sheep-associated malignant catarrhal fever. Res Vet Sci 1991, 50:38-44.
172. Patel J.R., Edington N. The detection and behaviour of the herpesvirus of malignant catarrhal fever in bovine lymphocytes. Arch Virol 1981, 68:321-326.
173. Bridgen A., Munro R., Reid H.W. The detectin of Alcelaphine Herpesvirus-1 DNA by in situ hybridisation of tissues from rabbits affected with malignant catarrhal fever. J Compar Pathol 1992, 106:351-359.
174. + αβ T cells, infiltrate vasculitis lesions of American bison (Bison bison) with experimental sheep-associated malignant catarrhal fever. Vet Immunol Immunopathol 2010, 136:284-291.
175. Dewals B., Boudry C., Famir F., Drion P.-V., Vanderplasschen A. Malignant catarrhal fever induced by alcelaphine herpesvirus 1 is associated with proliferation of CD8+ T cells supporting a latent infection. PLoS ONE 2008, 3(2):e1627.
176. Dewals B., Myster F., Palmeira L., Gillet L., Ackemann M., Vanderplaaschen A. Ex vivo bioluminescence detection of alcelaphine herpesvirus 1infection during malignant catarrhal fever. J Virol 2011, 85(14):6941-6954.
177. Rossiter P.B. Antibodies to malignant catarrhal fever virus in sheep sera. J Compar Pathol 1981, 91:303-311.
178. Rossiter P.B. Antibodies to malignant catarrhal fever virus in cattle with non-wildebeest associated malignant catarrhal fever. J Compar Pathol 1983, 93:93-97.
179. Piercy S.E. Studies in bovine malignant catarrha. IV. Immunity and vaccination. Br Vet J 1954, 110:87-96.
180. Plowright W. Malignant catarrhal fever. J Am Vet Med Assoc 1968, 152:795-804.
181. Plowright W., Herniman K.A.J., Jesset D.M., Kalunda M., Rampton C.S. Immunisation of cattle against the herpesvirus of malignant catarrhal fever: failure of inactivated culture vaccines with adjuvant. Res Vet Sci 1975, 19:159-166.
182. Edington N., Plowright W. The protection of rabbits against the herpesvirus of malignant fever by inactivated vaccines. Res Vet Sci 1980, 28:384-386.
183. Russell P.H. Malignant catarrhal fever in rabbits. Reproduction of clinical disease by cell free virus and partial protection against such disease by vaccination with inactivated virus. Vet Microbiol 1980, 5:161-163.
184. Mirangi P.K. Attempts to immunize cattle against virulent African malignant catarrhal fever virus (alcelephine herpesvirus-1) with herpesvirus isolated from American cattle. Vet Microbiol 1991, 28(2):129-139.
185. Haig D.M., Grant D., Deane D., Campbell I., Thomson J., Jepson C., et al. An immunisation stategy for the protection of cattle against alcelaphine herpesvirus-1 induced malignant catarrhal fever. Vaccine 2008, 26:4461-4468.
186. Herrewegh A.A., Smeenk I., Horzinek M.C., Rottier P.J., de Groot R.J. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol 1998, 72(5):4508-4514.
187. Hohdatsu T., Okada S., Ishizuka Y., Yamada H., Koyama H. The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 1992, 54:557-562.
188. Olsen C.W. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects and vaccination. Vet Microbiol 1993, 36:1-37.
189. Pedersen N.C. An overview of feline enteric coronavirus and infectious peritonitis virus infections. Feline Pract 1995, 23:7-20.
190. Haagman B.L., Egberink H.F., Horzinek M.C. Apoptosis and T-cell depletion during feline infectious peritonitis. J Virol 1996, 70:8977-8983.
191. Ward J.M., Gribble D.H., Dungworth D.L. Feline infectious peritonitis: experimental evidence for its multiphasic nature. Am J Vet Res 1974, 35:1271-1275.
192. Kipar A., Kohler K., Leukert W., Reinacher M. Evaluation of lymphatic tissue activity in cats with spontaneous feline infectious peritonitis. J Compar Pathol 2001, 125:182-191.
193. Stoddart C.A., Scott F.W. Isolation and identification of feline peritoneal macrophages for in vitro studies of coronavirus-macrophage interactions. J Leuk Biol 1988, 44(5):319-328.
194. Corapi W.V., Olsen C.W., Scott F.W. Monoclonal antibody analysis of neutralisation and antibody dependent enhancement of feline infectious peritonitis virus. J Virol 1992, 66:6695-6705.
195. Weiss R.C., Scott F.W. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue-hemorrhagic fever. Compar Immunol Microbiol Infect Dis 1981, 4(2):175-189.
196. Pedersen N.C. Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 1987, 218:529-550.
197. Ingersoll J.D., Wylie D.E. Identification of viral antigens that induce antibody responses on exposure to coronaviruses. Am J Vet Res 1988, 49:1467-1471.
198. Addie D., Belák S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg 2009, 11(7):594-604.
199. Gerber J.D., Ingersoll J.D., Gast A.M., Christanson K.K., Selzer N.L., Landon R.M., et al. Protection against feline infectious peritonitis by intranasal inoculation of a temperature sensitive FIPV vaccine. Vaccine 1990, 8:536-542.
200. Gerber J.D. Overview of the development of a modified live temperature sensitive FIP virus vaccine. Feline Pract 1995, 23:62-66.
201. Fehr D., Holznagel E., Bolla S., Hauser B., Herrewegh A.A., Horzinek M.C., et al. Placebo-controlled evalution of modified live virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine 1997, 15:1101-1119.
202. McArdle F.B., Tennat B., Bennett M., Kelly D.F., Gaskell C.J., Gaskell R.M. Independent evaluation of modified live FIPV vaccine under experimental conditions (University of Liverpool experience). Feline Pract 1995, 23:67-71.
203. Haijema B.J., Volders H., Rottier P.J.M. Live, attenuated coronavirus vaccine through the directed deletion of group specific genes provide protection against feline infectious peritonitis. J Gen Virol 2004, 78:3863-3871.
204. McCullough K.C, Ruggli N., Summerfield A. Dendritic cells- At the front-line of pathogen attack. Vet Immunol Immunopathol 2009, 128:7-15.
205. Ruggli N., Bird B.H., Liu L., Bauhofer O., Tratschin J.D., Hoffman M.A. Npro of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN α/ß induction. Virology 2005, 340:265-276.
206. Montgomery R.E. On a form of swine fever occurring in British East Africa (Kenya colony). J Compar Pathol 1921, 34:243-262.
207. Plowright W, Thomson GR, Nesser JA. African swine fever. In: Coetzer JAW, Thomson GR, Tustin RC, editors, Infectious diseases of livestock. Oxford: Oxford University Press; 1994. p. 568-599.
208. Plowright W. Vector transmission of African swine fever. In: Liess B, editor, Hog cholera/classical swine fever and African swine fever, EEC Publication EUR 5904 EN. Luxembourgh: Luxembourgh Office for Official Publications of the European Communities; 1977. p. 575-587.
209. Thomson G.R., Gainaru M.D., Van Dellen A.F. Experimental infection of warthog (Phacochoerus aethiopicus) with ASFV. Onderstepoort J Vet Res 1980, 47:19-22.
210. Ramiro-Ibanez F., Ortega A., Ruiz-Gonzalvo F., Escribano J.M., Alonso C. Modulation of immune cell populations and activation markers in the pathogenesis of African swine fever virus infection. Virus Res 1997, 47:31-40.
211. Oura C.A.L., Powell P.P., Parkhouse R.M.E. African swine fever: a disease characterised by apoptosis. J Gen Virol 1998, 79:1427-1438.
212. Oura C.A.L., Powell P.P., Anderson E., Parkhouse R.M.E. The pathogenesis of African swine fever in resistant bushpigs. J Gen Virol 1998, 79:1439-1443.
213. Dixon L.K., Abrams C.C., Bowick G., Goatley L.C., Kay-Jackson P.C., Chapman D., et al. African swine fever virus proteins involved in evading host defence systems. Vet Immunol Immunopathol 2004, 100:117-134.
214. Carrasco L., Gomez-Villamandos J.C., Bautista M.J., Martin de las Mulas J., Villeda C.J., Wilkinson P.J., et al. Apoptosis in lymph nodes in acute African swine fever. J Compar Pathol 1996, 115:415-428.
215. Ruiz-Gonzalvo F, Carnero ME, Bruyel V. Immunological responses of pigs to partially attenuated African swine fever virus and their resistance to virulent homologous and heterologous viruses. In: Wilkinson PJ, editor, African Swine Fever, EUR 8466 EN, Proceedings of CEC/FAO Research Seminar, Sardinia, Italy, September 1981, Luxemburg, Belgium 1983; p. 206-216.
216. Boinas F.S., Hutchings G.H., Dixon L.K., Wilkinson P.J. Characterisation of pathogenic and non-pathogenic African swine fever virus isolates from Ornithodoros erraticus inhabiting pig premises in Portugal. J Gen Virol 2004, 85:2177-2187.
217. Oura C.A.L., Denyer M.S., Takamatsu H., Parkhouse R.M.E. In vivo depletion of CD8+ T lymphocytes abrogates protective immunity to African swine fever virus. J Gen Virol 2005, 86:2445-2450.
218. Ruiz-Gonzalvo F., Rodriguez F., Escribano J.M. Functional and immunological properties of the baculovirus-expressed hemagglutinin of African swine fever virus. Virology 1996, 218:285-289.
219. Gomez-Puertas P., Rodriguez F., Oviedo J.M., Brun A., Alonso C., Escribano J.M. The African swine virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response. Virology 1998, 243:461-471.
220. Neilan J.G., Zsak L., Lu Z., Burrage T.G., Kutish G.F., Rock D.L. Neutralising antibodies to African swine fever virus proteins p30, p54 and p72 are not sufficient for antibody-mediated protection. Virology 2004, 319:337-342.
221. Ridpath J.F., Bolin S.R. Differentiation of types 1a, 1b and 2 bovine viral diarrhoea virus (BVDV) by PCR molecular and cellular probes. Mol Cell Probes 1998, 12:101-106.
222. Olafson P., MacCallum A.D., Fox F.H. An apparently new transmissible disease of cattle. Cornell Vet 1946, 36:205-213.
223. Hibberd R.C., Turkington A., Brownlie J. Fatal Bovine virus diarrhoea virus infection of adult cattle. Vet Record 1993, 132:227-228.
224. David G.P., Crawshaw T.R., Gunning R.F., Hibberd R.C., Lloyd G.M., Marsh P.R. Severe disease in adult cattle in UK dairy herds associated BVDV infection. Vet Record 1994, 134:468-472.
225. Patel J.R., Shilleto R.W., Williams J., Alexander D.C.S. Prevention of transplacental infection of bovine foetus by bovine viral diarrhoea virus through vaccination. Arch Virol 2002, 147:2453-2463.
226. Ramsey F.K., Chivers W.H. Symposium on the mucosal disease complex. II. Pathology of a mucosal disease of cattle. J Am Vet Med Assoc 1957, 130(9):381-833.
227. Brownlie J., Clarke M.C., Howard C.J. Experimental production of fatal mucosal disease in cattle. Vet Record 1984, 114:535-536.
228. Ridpath, JF. Bovine viral diarrhea virus. In: Mahy BWJ, van Regenmortel MHV, editors, Encyclopedia of virology, third edition. Oxford: Elsevier Science Publishers Ltd.; 2008. p. 374-380.
229. Potgieter L.N.D. Immunology of bovine viral diarrhea virus. Vet Clin N Am-Food Anim Pract 1995, 11:501-520.
230. Shahriar F.M., Clark E.G., Janzen E., West K., Wobeser G. Coinfection with bovine viral diarrhea virus and Mycoplasma bovis in feedlot cattle with chronic pneumonia. Can Vet J 2002, 43(11):863-868.
231. Patel J.R., Heldens J.G.M. Immunoprophylaxis against important virus diseases of horses, farm animals and birds. Vaccine 2009, 27:1797-1810.
232. Heldens J.G., Patel J.R., Chanter N., Ten Thij G.J., Gravendijck M., Schijns V.E., et al. Veterinary vaccine development from an industrial perspective. Vet J 2008, 178(1):7-20.
233. Callahan R., Lieber M.M., Todaro G.J., Graves D.C., Ferrer J.F. Bovine leukemia virus genes in DNA of leukemic cattle. Science 1976, 192:1005-1007.
234. Schultz RD, Duncan JR, Buxton BB. Immunocompetence in cattle with clinical leukosis (lymphosarcoma). In: Butler JE, editor, The ruminant immune system. Advances in experimental medical biology. New York: Plenum Press; 1981. p. 838-839.
235. Cockerell G.L., Parodi A.L., Levy D. Immunocompetence of sheep experimentally infected with bovine leukemia virus. Vet Immunol Immunopathol 1986, 13:189-202.
236. Payne S.L., Fang F.D., Liu C.P., Dhruva B.R., Rwambo P., Issel C.J., et al. Antigenic variation and lentivirus persistence: variation in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 1987, 161:321-331.
237. Payne S.L., La Celle K., Pie X.-F., Qi X.-M., Shao H., Steagall W.K., et al. Long terminal repeat sequences of equine infectious anaemia virus are a major determinant of cell tropism. J Gen Virol 1999, 80:755-759.
238. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation and continous production of cytopathic retroviruses HTLV III from patients with AIDS and pre-AIDS. Science 1984, 224:494-500.
239. Takeda A., Tuazon C.U., Ennis F.A. Antibody-enhanced infection by HIV via Fc-receptor-mediated entry. Science 1988, 242:580-583.